Novo Nordisk shared another incredible study on semaglutide (the active ingredient in Ozempic) last week. It turned out that the drug (intended for diabetes) not only reduces appetite and obesity, but also treats chronic kidney disease. It also reduces the risk of heart attack, death from type 2 diabetes, and kidney failure.
Source: https://finance.yahoo.com/news/novo-ozempic-slashes-risk-death-103000961.html
If thematic investing in healthcare (i.e. investing in the growing trends shaping our future) is your long-term strategy, glad for you:
Healthcare sector representing +3.13% YTD Return and +68.58% 5-Year Return as of now includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term-care facilities, and medical equipment and supplies, as well as pharmaceutical retailers and companies which provide health information services. Largest companies in this sector showing the highest YTD return are Eli Lilly and Company (LLY), Merck & Co.,Inc. (MRK) and Danaher Corporation (DHR).
submitted by /u/FXgram_
[link] [comments]